Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 385 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hip Arthrosis Clear all

Conditions: Arthroplasty
Interventions: Tapentadol IR (CG5503), Placebo, Oxycodone HCL IR; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 45
States / cities: Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 42 more

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg; Other · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more

Conditions: Hip Dysplasia
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 7 Years to 90 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Osteo Arthritis Knee
Interventions: Joint Insights decision aid; Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 45 Years to 89 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Arthroplasty, Replacement, Hip, Osteoarthritis, Hip
Interventions: Off Table Group, On Table Group; Procedure
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Knee Osteoarthritis, Hip Osteoarthritis
Interventions: Kaia hip and knee pain application, Treatment as usual; Behavioral · Other
Lead sponsor: Kaia Health Software; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Stamford, Connecticut

Conditions: Osteoarthritis, Hip
Interventions: Not listed
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis
Interventions: Modafinil, Gabapentin, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Sacroiliitis, Sacroiliac Joint Dysfunction, Iatrogenic Injury, Osteitis Condensans Ilii, Pelvic Fracture
Interventions: SiJoin® Transfixing Sacroiliac Fusion Device; Procedure
Lead sponsor: VG Innovations, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Naples, Florida

Conditions: Hip Dysplasia, Femoroacetabular Impingement, Acetabular Labrum Tear
Interventions: ropivicaine, clonidine, Epinephrine, Noropin; Drug
Lead sponsor: The Hawkins Foundation; Other
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Thromboembolism
Interventions: Rivaroxaban; Drug
Lead sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 5
States / cities: Denver, Colorado • Hollywood, Florida • Tamarac, Florida + 2 more

Conditions: Osteoarthritis
Interventions: Buprenorphine transdermal patch; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 42
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more

Conditions: Acute Blood Loss Anemia, Osteoarthritis, Hip
Interventions: Tranexamic acid, Placebo; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Femoroacetabular Impingement
Interventions: 3D Hip Model from Pre-operative CT scan; Other
Lead sponsor: The Hawkins Foundation; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: Tanezumab 2.5 mg, Tanezumab 5 mg, Tanezumab 10 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 679 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 100
States / cities: Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 70 more

Conditions: Osteoarthritis, Hip
Interventions: isobaric bupivacaine, hyperbaric bupivacaine, isobaric mepivacaine; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 84 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Bensalem, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Muscle Soreness, Headache, Knee Osteoarthritis, Back Pain, Neck Pain, Needle Stick, Shoulder Pain, Hip Osteoarthritis
Interventions: Observational dry needle; Other
Lead sponsor: Elizabeth Lane; Other
Eligibility: 18 Years to 100 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 8
States / cities: Acworth, Georgia • Cartersville, Georgia • Fort Oglethorpe, Georgia + 5 more

Conditions: Total Hip Arthroplasty
Interventions: Multi-Component Rehabilitation (CMC), Control (CON); Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Osteoarthritis
Interventions: Investigational Medical Product (IMP) administered in parent study; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 51
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 36 more

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: Engage PA, Treatment as Usual plus (TAU+); Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 65 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Osteoarthritis
Interventions: Diclofenac; Drug
Lead sponsor: Iroko Pharmaceuticals, LLC; Industry
Eligibility: 40 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 40
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 31 more

Conditions: Osteoarthritis of the Hip, Degenerative Joint Disease of Hip, Dysplasia; Hip
Interventions: Polymotion Hip Resurfacing (PHR) System; Device
Lead sponsor: JointMedica Inc.; Other
Eligibility: 21 Years to 65 Years
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Tampa, Florida • Chicago, Illinois • Baltimore, Maryland + 5 more

Conditions: Osteoarthritis, Traumatic Arthritis, Rheumatoid Arthritis, Congenital Hip Dysplasia, Avascular Necrosis of the Femoral Head, Acute Traumatic Fracture of the Femoral Head or Neck, Certain Cases of Ankylosis, Non-union of Femoral Neck Fractures, Certain High Sub-Capital & Femoral Neck Fractures in Elderly
Interventions: Actis Total Hip System; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 21 Years and older
Enrollment: 266 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2024
U.S. locations: 9
States / cities: Louisville, Kentucky • Boston, Massachusetts • Rochester, Minnesota + 6 more

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: REGN475, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 72
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 69 more

Search by objective public record fields.

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

Discovering the Gene(s) Causing Developmental Dysplasia of the Hip (DDH)

Incorporating Patient-Reported Outcomes Into Shared Decision Making With Patients With Osteoarthritis of the Hip or Knee

On-Table Versus Off-Table Total Hip Arthroplasty

The Kaia Hip and Knee Pain Intervention for Self-management of the Pain in Patients With Osteoarthritis.

Comparison of Muscle Atrophy After Direct Anterior & Posterior Total Hip Arthroplasty

Pain Expectations in Subjects With Osteoarthritis

Clinical Outcome and Fusion Results Using the SiJoin® Transfixing Sacroiliac Fusion Device

Hip Scope Fascia-iliaca (FI) Block Study

Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement

Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase

Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty

3D Modeling to Improve Hip Arthroscopy Outcomes

A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

3 Local Anesthetics for Spinal Anesthesia in Primary Total Hip Arthroplasty

Adverse Events in Dry Needling

Strength and Function Following Total Hip Arthroplasty

Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement

Increasing Physical Activity in Older Adults With Osteoarthritis Pain: Examining a Brief Behavioral Intervention

Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain

Evaluate the Safety and Effectiveness of the Polymotion Hip Resurfacing (PHR) System Compared to Total Hip Arthroplasty

Actis Total Hip System 2 Year Follow-up

Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip